Medication Comparison
Semaglutide vs Orforglipron
Orforglipron could be a game-changer as an oral small-molecule GLP-1 that approaches injectable semaglutide's weight loss (~14% vs ~15%). Unlike Rybelsus (oral semaglutide), orforglipron is a small molecule that is easier and cheaper to manufacture. If approved, it could dramatically lower the cost of GLP-1 therapy and eliminate the need for injections.
| Category | Semaglutide | Orforglipron |
|---|---|---|
| Brands | Ozempic / Wegovy | Not yet approved (Eli Lilly) |
| Class | GLP-1 RA (peptide) | GLP-1 RA (small molecule, oral) |
| Administration | Weekly injection | Daily oral tablet |
| Average weight loss | ~15% | ~14% |
| Compounded cost | $150-400/mo (compounded) | Not yet available |
| Brand cost | $1,000-1,400/mo | Not yet available (expected to be cheaper than injectables) |
| Half-life | ~7 days | ~29 hours |
| Dosing frequency | Once weekly | Once daily |
| Key trial | STEP 1 (16.9% weight loss) | Phase 2 (up to 14.7% weight loss at 36 weeks) |
Best for Semaglutide
Patients who need effective treatment available today
Best for Orforglipron
Future option for patients who want injectable-level results from a daily pill
Semaglutide tradeoffs
Pros
- FDA-approved and available now
- Extensive safety data
- Proven cardiovascular benefits
Cons
- Requires injection
- Peptide-based (cold chain required)
- Expensive at brand pricing
Orforglipron tradeoffs
Pros
- Oral pill (no injections)
- Small molecule (easier to manufacture, no cold chain)
- May be cheaper to produce at scale
Cons
- Not yet approved
- Slightly less weight loss in early data
- Daily dosing required
Common questions
When will orforglipron be available?
Eli Lilly is conducting Phase 3 trials (ACHIEVE program). If successful, FDA approval could come in 2026-2027. It would be the first oral small-molecule GLP-1 for obesity.
How is orforglipron different from Rybelsus?
Rybelsus is oral semaglutide (a peptide that needs special absorption enhancement and fasting). Orforglipron is a small molecule — it absorbs more easily, doesn't require fasting, and is much cheaper to manufacture.
Could orforglipron make GLP-1s affordable?
Potentially, yes. Small molecules are far cheaper to produce than peptides. Without cold chain requirements and with simpler manufacturing, the cost could be significantly lower than current injectable GLP-1s.
Compare clinics that prescribe these medications
Use provider pages to compare clinical oversight, medication source, and pricing transparency before starting.
Related comparisons